RR

Richard Ransohoff

Founder of Abata Therapeutics

Greater Boston

Overview 

Richard Ransohoff is a Co-founder and Clinical Advisor at Abata Therapeutics and a Venture Partner at Third Rock Ventures in Greater Boston. With a background in neurology and extensive experience in the biotech industry, he has played a key role in founding Abata Therapeutics and has made impactful investments in the bioTech sector, particularly in Series A stages. Ransohoff's career highlights include serving as the Co-founder and Chief Medical Officer at Abata Therapeutics and holding a VP position at Biogen, showcasing his expertise in neurodegenerative diseases and his ability to drive innovation and growth in the healthcare industry.

Work Experience 

TR

Third Rock Ventures

  • Venture Partner

    2019 - Current

  • Entrepreneur In Residence

    2018 - 2019

AT

Abata Therapeutics

  • Co-founder and Chief Medical Officer

    2021

Abata Therapeutics develops regulatory T cell (Treg) therapies for treating autoimmune diseases including progressive multiple sclerosis.

Raised $95,000,000.00 from Bristol-Myers Squibb.

abatatx.com
B

Biogen

  • VP

    2014 - 2017

    My responsibility at Biogen as VP, and Research/Early Development Unit Head for Neuroimmunology & MS/Pain/Acute Neurology ([NIPAN]; 2014-2017) entailed leading a group of >45 scientists and clinicians in finding and prosecuting neuroinflammatory targets for treatment of neurological disease and pain, and bringing those relevant for acute neurology indications through phase II proof of concept (PoC). During this time, I led the transformation of the neuroinflammation portfolio, successfully bringing 5 compounds (internally developed and externally identified) into the clinic as well as directing activities in blood-brain barrier (BBB) function, progressive multifocal leukoencephalopathy (PML) risk mitigation and novel screening technologies for glial targets, in addition to basic neuroinflammation biology.

Biogen is a biotechnology company engaged in the development of innovative therapies for neurological and neurodegenerative diseases.

biogen.com

Lerner Research Institute, Cleveland Clinic

  • Member Of Scientific Staff

    1989 - 2014

Cleveland Clinic

  • Neurologist

    1984 - 2014

    Staff Neurologist, Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic. Named in "Best Doctors" 1996-2014"

Education 

Investments 

Abata Therapeutics

Series A

Total funding: $95M

Articles About Richard

Relevant Websites